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Abstract: Bronchiectasis is characterised by airflow obstruction and hyperinflation resulting in res-
piratory muscle weakness, and decreased exercise capacity. Inspiratory muscle training (IMT) is
potentially an alternative treatment strategy to enhance respiratory muscle strength and endurance.
Therefore, the aim was to investigate the effects of IMT on those with bronchiectasis. Eighteen
participants (10 bronchiectasis) took part in an eight-week, three times a week IMT programme at
80% sustained maximal inspiratory pressure (SMIP). Lung function, respiratory muscle strength and
endurance, exercise capacity, physical activity and self-determination theory measures were taken.
Participants also took part in a semi-structured interview to assess their perceptions and experience
of an IMT intervention. After eight weeks of IMT, bronchiectasis and healthy participants exhibited
significant increases in MIP (27% vs. 32%, respectively), SMIP (16% vs. 17%, respectively) and inspi-
ratory duration (36% vs. 30%, respectively). Healthy participants exhibited further improvements
in peak expiratory flow and maximal oxygen consumption. Bronchiectasis participants reported
high levels of perceived competence and motivation, reporting higher adherence and improved
physical ability. Eight weeks of IMT increased inspiratory muscle strength and endurance in those
with bronchiectasis. IMT also had a positive effect on perceived competency and autonomy, with
bronchiectasis participants reporting improved physical ability and motivation, and high adherence.
Keywords: bronchiectasis; inspiratory muscle training; chronic disease; respiratory; quality of life;
mixed methods
1. Introduction
Bronchiectasis is a chronic pulmonary disease characterised by airflow obstruction due
to the destruction of elastic tissue and smooth muscles of the bronchial walls [1,2], arising
from a vicious cycle of transmural infection and inflammation [3]. Primary symptoms
include cough, excessive secretions, dyspnoea, exercise intolerance and fatigue [4,5]. These
symptoms may, at least in part, be attributable to respiratory muscle weakness also reported
in those with bronchiectasis [5–8], which may lead to discord between respiratory muscle
load and capacity [6]. Indeed, decreased respiratory muscle strength is associated with less
productive coughing and decreased removal of airway secretions [8,9]. Effective strategies
to target and resolve respiratory muscle weakness are therefore needed for those with
bronchiectasis.
Pulmonary rehabilitation (PR) has been recommended for those with bronchiectasis.
However, patient perceptions on the effects of PR are limited [10]. Nonetheless, following
improvements in physical and psychological health post-PR, Sinnerton and Gillen [11] also
reported enhanced patient confidence and less dependency on medical resources. However,
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exacerbations, transport difficulties and lack of motivation were highlighted as barriers
to participation in, and adherence to, PR. Inspiratory muscle training (IMT), utilising a
restricted airflow breathing technique, has often been used as an adjunct to traditional
PR programmes in chronic obstructive pulmonary disease (COPD), leading to greater
improvements in exercise capacity than PR in isolation [12,13]. However, whether similar
benefits are elicited by IMT in those with bronchiectasis is less clear. Specifically, whilst
some report improvements in respiratory muscle strength and endurance, exercise capacity
and social aspects of quality of life following IMT [6], others have reported beneficial
effects to be limited to improvements in inspiratory and expiratory muscle strength [7],
or there to be no additional benefits to those associated with traditional PR in those with
bronchiectasis [5]. Moreover, home-based IMT in chronic lung diseases has been shown
to have a positive impact on activities of daily living, mobility, and breathlessness, with
patients becoming more confident in managing their disease [10]. Therefore, investigating
patient perceptions and motivations to participate in an intervention, in conjunction with
determining associated physiological and psychological effects, is essential when evaluat-
ing the overall effectiveness of an intervention. Overall, further work is required to resolve
these equivocal findings, which may be related to considerable methodological differences,
such as participant adherence to the IMT protocol, which no study has reported, or the
intensity, frequency or duration of the IMT used. Indeed, in those with COPD, interval-
based, high-intensity IMT has been shown to elicit greater improvements in respiratory
muscle function than low- to medium-intensity protocols [14,15].
The long-term nature of bronchiectasis means that patients must cope with the de-
bilitating nature of their disease over the course of their lives [16]. Indeed, patients with
bronchiectasis have reported reduced quality of life and increased symptoms of anxiety
and depression [17,18]. Feelings of anxiety have been associated with patients’ perceptions
of their health and well-being, whereas depression is suggested to be linked to exercise
impairment and breathlessness [18]. Therefore, interventions that improve both patient
perceptions and exercise capacity, whilst relieving symptoms of breathlessness, are of
paramount importance to the psychological health of patients with bronchiectasis.
Therefore, the aim of the current study was to determine the physiological and psycho-
logical effect of an eight-week home-based IMT intervention in adults with bronchiectasis.
The secondary aim was to evaluate participants’ adherence to the IMT protocol and their
experiences and perceptions of this type of pulmonary rehabilitation programme.
2. Materials and Methods
Ten clinically stable bronchiectasis patients, diagnosed by clinical history including
high-resolution tomography, pulmonary functions tests, cough, shortness of breath and
exertional dyspnoea, were recruited from an outpatient clinic in South Wales to take part
in this quasi-experimental trial. Eight healthy participants were recruited from university
networks and were required to have no pulmonary or respiratory conditions that may
impair exercise capacity. Ethical approval was granted by the North Wes—Liverpool
Central Research Ethics Committee (reference 16/NW/0764) and written informed consent
was obtained from all participants. Participants were required to attend a testing session at
baseline and one following the eight-week intervention. For participants who agreed to
take part in an eight-week IMT top-up, a third visit was required at week 16.
2.1. Inspiratory Muscle Training Intervention
The PrO2Fit device (PrO2 Health Incorporated, Rhode Island, NE, USA) was chosen
due to its ability to provide biofeedback and remote adherence monitoring as well as
its capacity for greater IMT workloads throughout the full range of inspiration using a
decreasing rest period between breaths [19]. Prior to completing the intervention, partici-
pants were given a ~30 min familiarisation training session on how to use the device and
the inspiratory manoeuvre technique in order to minimise possible learning effects [20].
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The PrO2Fit device incorporates a 2 mm leak to avoid glottal closure during maximal
inspiration [21].
At the start of every IMT training session, participants were instructed to complete a
baseline maximal manoeuvre to determine their sustained maximal inspiratory pressure
(SMIP). Participants were then required to train at 80% of their SMIP throughout each inspi-
ratory effort, thereby facilitating an individualised and progressive nature of training [22].
Inspiratory duration was also measured for each breath. Each IMT session involved up to
six blocks of six inspirations, with the rest between inspirations in each block progressively
decreasing from 60 s to 45, 30, 15, 10, and, finally, 5 s [22]. If participants failed to achieve
80% SMIP, the training session was automatically terminated. Training was performed
three times per week, with a least 24 h between sessions, for eight weeks. At the end of the
eight weeks, participants were given the option to complete a further eight weeks during
which they were asked to complete IMT once a week. All training sessions were uploaded
automatically to the cloud allowing remote monitoring.
2.2. Anthropometrics
Physical characteristics including body mass (Seca 220; Hamburg, Germany) and
stature were measured to the nearest 0.1 kg and 0.01 m, respectively, with body mass
index (BMI) subsequently calculated. Waist and hip circumference were measured to the
nearest 0.01 m using an anthropometric tape (Seca, Birmingham, UK) at the narrowest
point between the base of the ribs and the iliac crest for waist circumference, and the widest
point around the hips for hip girth. Waist-to-hip ratio (WHR) was subsequently calculated.
2.3. Physiological Measures
Parameters of respiratory function forced expiratory volume in one second (FEV1),
forced vital capacity (FVC), FEV/FEV1 and peak expiratory flow (PEF) were assessed in
a sitting position using a portable spirometer (Micro1, MicroRPM, Kent, UK), measured
according to European Respiratory Society Task Force guidelines [23]. Respiratory muscle
strength was measured using a portable electronic mouth pressure device (Micro Medical
MicroRPM, Kent, UK), with maximal inspiratory pressure (MIP) measured at residual
volume and maximal expiratory pressure (MEP) determined at total lung capacity. Each
participant was required to complete three maximal inhalations and exhalations; differences
greater than 10% or 10 cm H2O required an additional effort, with the best inspiration and
exhalation selected for subsequent analysis. FEV1 and FVC were also expressed as the
percentage predicted for age, stature and gender [23,24].
If able, participants were asked to complete an incremental ramp test on a cycle
ergometer (ViaSpint 150P; ViaSys Healthcare, Germany) to volitional exhaustion. Following
a three minute warm-up at 10 W, the resistance was progressively increased at 10 W·min−1.
Participants were required to maintain a cadence ~60–70 revolutions per minute (rpm)
throughout the test, with the test terminated when the cadence decreased by >10 rpm,
despite strong verbal encouragement. Subjective ratings of perceived exertion (RPE)
were recorded every minute [25]. Subsequently, participants completed a supramaximal
validation bout at 110% of peak power output achieved during the initial cycle ergometer
test. Breath-by-breath pulmonary gas-exchange data were collected continuously during
the incremental and supramaximal exercise tests (MetaMax 3B, Cortex Medical, Leipzig
Germany). Participants were required to wear a facemask, breathing through an impeller
turbine assemble (Jaeger Triple V, Hoechberg, Germany), with gas volumes and flow rates
continuously sampled at 100 Hz.
2.4. Psychological Measurements
Employing self-determination theory [26] all participants completed questionnaires to
assess treatment self-regulation and perceived competence in relation to IMT, following
the initial eight-week intervention. Specifically, the 15-item treatment self-regulation
questionnaire was utilised to assess reasons for completing IMT regularly (i.e., “The reason
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I would undertake IMT is because I feel that I want to take responsibility for my own
health”). The treatment self-regulation questionnaire has three subscales: autonomous
regulation, controlled regulation and amotivation. Perceived competence was measured
using four single-item indicators (i.e., “I feel confident in my ability to undertake IMT
regularly”). Both questionnaires were answered using a Likert scale ranging from one (not
at all true) to seven (very true) and are validated for use within clinical populations [27].
Finally, participants were invited to complete a face-to-face, semi-structured interview
following the eight-week intervention. If participants failed to complete the intervention,
they were still invited to take part in an interview to ascertain their perceptions and barri-
ers to completing the intervention. The interviewer (JMC) asked open-ended questions,
seeking clarification or elaboration when required. Questions were centred around their ex-
perience with IMT, recommendations for future use and more generic opinions of physical
activity and exercise. Interviews were audio recorded and transcribed verbatim.
2.5. Data Analysis
2.5.1. Cardiopulmonary Exercise Testing and Supramaximal Verification
Oxygen consumption (
.
VO2) and carbon dioxide production (VCO2) were converted
to 15 second averages. The highest moving average of Vo2 measured over 15 second
was taken as the peak value. The gas-exchange threshold (GET) was determined as the
.
VO2 at which there was a non-linear increase in carbon dioxide consumption relative to.
VO2, with an increase in minute ventilation (VE)/
.
VO2 without a concomitant increase in
VE/VCO2 [28] Peak
.
VO2 was considered maximal if the Vo2 peak achieved during the
supramaximal verification did not exceed that achieved during the ramp test by ≥9% [29].
2.5.2. Interview Analysis
All interviews were transcribed verbatim by JLM, using a manual method [30], with
interview data analysed using an inductive and deductive approach via direct content
analysis [31]. Transcripts were coded line by line and then placed in a relevant overarching
category. To ensure a detailed account of participants experiences, similar and/or opposing
codes were then organised into themes. An independent author (KAM) undertook a
cross-examination of the data to challenge the interpretations, ensuring methodological
rigour and that findings were logical and to offer alternative interpretations [32,33]. This
process was repeated until an acceptable consensus was reached. The triangular consensus
procedures afforded credibility and transferability [34].
2.6. Statistical Analysis
All data were analysed using IBM SPSS (IMB Corp, Version 25.0. Armonk, New York:
IBM Corp) and are presented as the mean ± standard deviation (SD) unless stated other-
wise. Statistical significance was accepted as p < 0.05. A repeated-measures ANOVA was
used to determine the influence of IMT, and how this differed by group. Pearson’s correla-
tion coefficients were used to assess the relationships between Vo2max, and lung function.
The minimal clinically important difference (MCID) was calculated using distribution-
based methods. Specifically, the baseline SD multiplied by 0.5 was used to determine
whether IMT had a clinically significant effect on lung function, and peak
.
VO2. The
change score divided by the baseline SD score was used to calculate effect size, with Co-
hen’s d (1988) [35] thresholds used for interpretation (small = 0.2, moderate = 0.5 and
large = 0.8).
3. Results
Fourteen adults with clinically stable bronchiectasis agreed to take part in this study.
One patient withdrew due to an acute exacerbation, two withdrew due to the inability
to use the device and one was unable to make the retesting visits. Due to the impact of
COVID-19, eight healthy participants could not be retested, but they were invited to take
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part in interviews. Overall, adherence to the IMT protocol was high, with bronchiectasis
patients completing significantly more IMT sessions (95%) than the healthy participants
(80%) during the first eight weeks.
The healthy participants were younger than those with bronchiectasis who were
characterised by a higher BMI at baseline (Table 1). Furthermore, healthy participants
exhibited a higher MEP (p = 0.05), FEV1 (p = 0.002), FVC (p = 0.002), FVC %predicted
(p = 0.03) and Vo2max (p = 0.002; Table S1).
Table 1. Baseline anthropometrics of adults with bronchiectasis and healthy participants.




(n = 8) p Value
Anthropometrics
Age (years) 51.9 ± 17.2 64.5 ± 10.3 36.1 ± 8.5 <0.05 *
Sex (female/male) (5/13) (3/7) (2/6) 0.886
Height (cm) 172.6 ± 10.9 169.5 ± 11.2 176.4 ± 9.7 0.183
Weight (kg) 76.9 ± 16.8 81.2 ± 19.7 71.5 ± 11.2 0.238
BMI (kg·m−2) 25.8 ± 5.5 28.3 ± 6.3 22.8 ± 1.8 0.024 *
WHR (cm) 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.6 0.106
BMI, body mass index; WHR, waist-to-hip ratio. * p < 0.05 (significant difference between Bronchiectasis and
Healthy groups).
3.1. Effects of Inspiratory Muscle Training
A repeated-measures ANOVA with Greenhouse–Geisser correction showed that eight
weeks of IMT was associated with a main effect of time and group for MIP, SMIP and
inspiratory duration, with a significant group-by-time interaction for PEF and Vo2max
(p < 0.05). Specifically, bronchiectasis and healthy participants exhibited significant increases
in MIP (27% vs. 32%, respectively), SMIP (16% vs. 17%, respectively) and inspiratory
duration (36% vs. 30%, respectively) after eight weeks of IMT. The healthy participants
also exhibited further improvements in PEF and Vo2max after eight weeks, which were not
evident in the bronchiectasis group (Figure 1; Table S1).
MCID revealed that bronchiectasis patients exhibited small clinically meaningful
improvements in MIP, SMIP and HGS (d = 0.4; d = 0.2; d = 0.2, respectively) and a moderate
clinically meaningful improvement in inspiratory duration (d = 0.6) following IMT. There
were no clinically meaningful improvements in any other parameters (Table 2).
Following the eight-week IMT intervention, MIP significantly correlated with FEV1
(r = 0.667; p = 0.035) and FVC (r = 0.772; p = 0.009), whilst Vo2max showed significant
correlations with FEV1 (r = 0.693; p = 0.039) and FEV1/FVC (r = 0.795; p = 0.018) in those
with bronchiectasis. Contrastingly, in the healthy participants, MIP correlated with MEP
(r = 0.821; p = 0.012), whilst FEV1 was significantly correlated with FVC (r = 0.721; p = 0.044).
Compared to healthy participants, those with bronchiectasis exhibited significantly
higher levels of autonomy (4.9 ± 1.4 vs. 2.1 ± 0.7; p < 0.01) and perceived competence
(5.5 ± 1.3 vs. 4.6 ± 1.1; p < 0.01), with lower levels of amotivation (1.4 ± 0.6 vs. 4.3 ± 0.4;
p < 0.01) after eight weeks of IMT (Table 3).
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MIP (cmH2O) 19.6 ± 18.9 * 40% 0% 0.4 23.7 ± 27.5 0% 33% 0.5
MEP (cmH2O) 3.2 ± 20.3 20% 10% 0.1 4.7 ± 4.1 0% 0% 0.2
SMIP (PTU) 66.1 ± 57.8 * 50% 0% 0.7 65.8 ± 57.6 0% 0% 0.2
ID (s) 3.8 ± 4.0 * 60% 0% 0.2 3.4 ± 4.1 0% 0% 0.1
FEV1 (l) 0.01 ± 0.2 0% 0% 0.01 0.1 ± 0.1 0% 0% −0.1
FEV1 %predicted 0.4 ± 11.7 30% 60% 0.02 7.0 ± 6.7 67% 0% 0.5
FVC (l) 0.01 ± 0.2 10% 0% −0.02 0.1 ± 0.1 0% 0% −0.2
FVC %predicted −2.0 ± 14.1 40% 40% −0.2 9.0 ± 13.1 33% 0% 0.9
PEF (L·min−1) 5.0 ± 49.7 20% 10% 0.04 5.0 ± 9.5 0% 0% −0.04




0.1 ± 1.7 10% 10% −0.04 4.3 ± 5.1 0% 100% 2.0
MIP, maximal inspiratory pressure; MEP, maximal expiratory pressure; SMIP, sustained maximal inspiratory pressure; PTU, pressure time unit; ID, inspiratory duration; s, seconds; FEV1, forced expiratory
volume in one second; FVC, forced vital capacity; PEF, peak expiratory flow; Vo2max, maximal oxygen uptake. * p < 0.05.
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19.6 ± 18.9 *  40%  0%  0.4  23.7 ± 27.5  0%  33%  0.5 
MEP 
(cmH2O) 
3.2 ± 20.3  20%  10%  0.1  4.7 ± 4.1  0%  0%  0.2 
SMIP (PTU)  66.1 ± 57.8 *  50%  0%  0.7  65.8 ± 57.6  0%  0%  0.2 
Figure 1. Changes in (A) maximal inspiratory pressure (MIP); (B) sustained maximal inspiratory pressure (SMIP); (C) peak
expiratory flow (PEF) and (D) inspiratory duration over the eight weeks of an inspiratory muscle training intervention in
adults with bronchiectasis and healthy controls. Grey columns represent the mean group response with standard deviation
bars. Overlaid lines represent individual responses.
Table 3. Self-determination measures after eight weeks of inspiratory muscle training.
8 Weeks 95% Confidence Interval p Valuebetween Groups
Bronchiectasis Healthy MeanDifference SEM Lower Upper
Treatment Self-Regulation
Autonomous 4.9 ± 1.4 * 2.1 ± 0.7 2.8 0.5 1.7 4.0 <0.01 *
Controlled 1.7 ± 0.7 1.5 ± 0.3 0.2 0.3 −0.4 0.8 0.411
Amotivation 1.4 ± 0.6 4.3 ± 0.4 * −2.9 0.3 −3.4 −2.4 <0.01 *
Perceived
Competence 5.5 ± 1.3 * 4.6 ± 1.1 0.9 0.6 −0.31 2.1 0.128
SEM, standard error of the mean. * p < 0.05 within group differences.
3.2. Eight-Week Top-Up Period
Five bronchiectasis and four healthy participants agreed to take part in a further
eight-week top-up period. Two bronchiectasis patients subsequently dropped out of the
top-up period; one participant was going on vacation and the other had purchased their
own PrO2 and wanted to train more frequently. Two healthy participants also dropped
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out due to being unable to make the final testing visit. Adherence in those that completed
the entire top-up period was 100% and 69% for bronchiectasis and healthy participants,
respectively.
There were no significant differences in respiratory muscle strength, lung function
parameters or exercise capacity between or within groups compared to the values following
the initial eight weeks after the eight-week top-up period.
3.3. Qualitative Experiences
Key themes derived from the interviews with bronchiectasis and healthy partici-
pants are presented below. ‘B’ indicates quotes from bronchiectasis and ‘H’ from healthy
participants.
3.3.1. Relationship with Physical Activity and Exercise
Positives
Most bronchiectasis participants (80%) and all healthy participants (100%) highlighted
a positive relationship with physical activity and exercise, citing experiences of both mental
and physical enjoyment:
“I love walking the dogs, because it gets you out into the open air . . . it is good
for you mentally as well I think. It does make you feel better doesn’t it? You feel
very virtuous when you’ve done some [physical activity].” [B10]
“I like the freedom of it . . . I find it really helpful for my mental health. The
knowledge that my body is capable of doing things. I like the sense of achieve-
ment.” [H1]
Barriers to Exercise
Symptoms associated with bronchiectasis were highlighted as the main barrier to
exercise in this cohort of patients:
“Having this bronchiectasis limits the amount of physical activity and exercise
I can do . . . I look forward to it [physical activity and exercise] mentally, but I
am very much aware of my limitations very soon . . . I wish I could do a lot more
walking and I would really enjoy that much more if I could.” [B3]
With their condition impacting on their activities of daily living:
“I’ve got to take my time on everything, but anything that’s up and down, I mean
like the stairs, up is physical, but down is just as hard.” [B1]
In line with the healthy participants, barriers such as enjoyment, weather, work and
time constraints were also highlighted as reasons for being inactive:
“I don’t enjoy it [physical activity], I haven’t got the time to do it. It’s time more
than anything [that is a barrier], you come home from work and you’re tired, you
don’t want to start doing exercises.” [B6]
“Time is always the biggest one [barrier to exercise and physical activity]. It
always is isn’t it? Time and mental sort of motivation . . . One of the downsides
of my job is that I’m spending a lot of time sitting down. I’ve come from a
previously very active job . . . to then go to a really sedentary job has been really
hard and that’s really affected my activity.” [H5]
Motivations to Exercise
Despite these limitations and the barriers to physical activity and exercise, patients un-
derstood the importance of being physically active and also highlighted their bronchiectasis
as a motivator to be active:
“Since the diagnosis I realise I need to be more active in order to keep my lungs
healthy and the sputum moving around... So, the more active you are the better
it [bronchiectasis] is. I try to be a little bit more active, whereas before [diagnosis]
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I might have thought ‘I won’t do any exercise tonight’, I think ‘right I’ve got to
do it because of the bronchiectasis’.” [B10]
Another critical motivator was being healthy for family reasons:
“The idea, certainly with the grandchildren, is to be as fit as you can around
them so that you can keep up with them! It has been quite physically demanding
[looking after the grandchildren].” [B8]
In line with the bronchiectasis participants, healthy adults also highlighted an under-
standing of the importance of exercise:
“The benefit [of exercising] is I know it is good for me. It’s probably the best drug
in the world, if you could bottle it. I do it for my own health and that it makes
me feel better about myself.” [H5]
External Influences
External influences to exercise also centred around health, implications of ageing and
the impact a person’s health can have on others:
“I think there is a moral obligation to exercise and at least remain healthy, because
it matters to other people what happens to us. Obesity and smoking causes
demand on the health service . . . problems just get worse as you get older and
then it drags other people in because they have to look after you . . . It’s a drag
on your friends and relatives and you have to consider the effect of your own
decisions on other people.” [H9]
Furthermore, the social aspect and the influences of others were also highlighted as
an external motivator to exercise:
“It depends who you hang around with. If you hang around with lots of sports
people you tend to learn off your group. Whereas, if you haven’t got that social
side to it, then maybe you won’t exercise as much.” [H1]
Some healthy participants also discussed the pressures they feel to be active, citing
external influences such as media, society pressures and weight control:
“If I wasn’t particularly active, I think I would feel guilty. I don’t know if that
is something that is put on me myself or more because of the media aspect . . .
I’m probably going to have more health complications, probably going to be
overweight. I don’t know if it is a societal thing or a personal thing [pressure to
be active], but I’d feel guilty if I didn’t [exercise].” [H1]
3.3.2. Inspiratory Muscle Training Intervention
Enjoyment
Bronchiectasis participants expressed ‘enjoyment’ of undertaking IMT and that it was
something they ‘looked forward’ to due to the perception it could help their health:
“I was looking forward to doing it, because I want to do anything that’s going to
help. I’ve been so poorly with my chest this year that anything that will help, I
will try.” [B2]
Motivations
Bronchiectasis patients discussed determination and motivation to take part in the
training, due to the structure of the training programme:
“I was determined, I wanted to do this [IMT] . . . the main reason is that it gives
me that discipline, I am more than happy to follow a training programme and
then the motivation followed ‘I will do this’.” [B3]
Participants enjoyed the high-intensity nature of the training and discussed how
the differing levels and reducing rest times were ‘challenging’ but motivated them to try
harder:
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“They [decreasing rest times] were good. That really set a goal for you, you know.
It was hard, but I was motivated to do it, it did push you a bit more!” [B1]
“That made it harder at the time [levels and decreasing rest times]. I think it
was good, it kept it more engaging . . . it kind of has a reward element to it, I
suppose.” [H9]
In contrast to bronchiectasis, while some enjoyed the IMT intervention, more healthy
participants discussed having less motivation to complete training compared to regular
exercise, due to the lack of intrinsic and extrinsic rewards:
“Less motivated to do it [IMT] than I am to do exercise. I think once you’ve
done exercise you feel good about it afterwards, you feel like you have achieved
something. Whereas, after doing the PrO2 training, it just felt like something that
I had to do, I had to get through, but no reward at the end.” [H1]
The reasons for this lack of motivation were due to participant’s perceived lack of
improvements from undertaking IMT, with healthy participants suggesting that clinical
populations or athletes may benefit from this style of training more:
“I’m guessing you might get more significant results if someone sort of sedentary
was using it. I don’t feel like it was helping me in anything other than being able
to do the test better.” [H6]
Accessibility
The remote nature of the training programme was a positive for the participants as it
allowed easy integration into their daily lives, with participants reporting that if it was not
home-based, they would not have taken part:
“If I had to go somewhere to use it, I probably would not have done it . . . I
would have had to have made more of an effort and having something small and
portable, why would I want to go somewhere else with it?... Having it at home I
can do it easily” [B4]
Similarly, the convenience of being able to train at home was also discussed by healthy
participants as a positive of the intervention:
“I think it’s better to have it at home than having it elsewhere, it would never
have worked [training elsewhere] . . . It’s just convenient really, doing it at your
own time at your own pace without anyone watching.” [H2]
Healthy participants also discussed the ease of training and how easily it can be
integrated into daily routine:
“It’s quite portable and convenient as opposed to setting an hour of your day
aside to physically go and do exercise . . . It’s a lot more flexible in terms of time
of day or motivation. You can adapt to it quite well.” [H10]
Feedback
Another highlight of the training was the accompanying app and the live feedback
loop it provided. All participants cited this as a critical motivating factor, while giving
them a chance to set their own goals:
“You can set your goals then . . . I found having that sort of feedback was very
helpful” [B7]
“It [feedback] changed my behaviour for the better, I was aiming for something,
I knew what I was meant to be doing. I think having that goal in mind helps the
person try and exercise.” [H7]
While it gave participants an opportunity to track their own progress, it also brought
out the competitive nature of some participants:
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“It is nice to know how you are doing, but it’s also nice to have something to
compete against. If somebody would have asked me before ‘are you competitive’?
I would have said no, not really, but yes, in this instance I certainly am!” [B5]
Participants also highlighted that if they did not have this extrinsic motivation, they
would not have trained or have been as motivated to try as hard as they perceived they did:
“You wouldn’t have pushed yourself as much [if you didn’t have the visual
feedback]” [B4]
“I wouldn’t have tried as hard because you don’t know how you’ve done. You
wouldn’t be as motivated to try then.” [H2]
However, healthy participants also discussed the negative aspects of the feedback
element and how it could also potentially be demotivating:
“Then I got really frustrated if I couldn’t get to the end.” [H4]
3.3.3. Perceived Improvements
Importantly, all bronchiectasis participants perceived an improvement in their physical
ability and health after completing IMT, attributing this solely to the training programme:
“I’m not doing anything different in my life other than using the device . . . Some
of the things I do now, the recovery time after doing them is about half [the
recovery time] was before. I have never got this far into a winter without a cold
turning into a chest infection. My lungs aren’t producing the same levels of
mucus as they typically do which is a great improvement. Physically I’m feeling
better, now that’s [IMT] got to be worth doing.” [B8]
Activities of daily living were also perceived to be easier:
“My stamina has got better I would say that, I was quite pleased with that actually.
I found it easier walking up the stairs, I was fitter. It’s all hills round me and
two months ago I wouldn’t have been able to do an hour [walk] . . . but now it’s
ok!” [B1]
Bronchiectasis participants also voiced the ability to expectorate sputum more easily,
which they felt led to a decrease in recurrent respiratory infections:
“What I like about it was that it helped me to clear a lot of sputum much better
than the Acapella [an airway clearance device] . . . I haven’t had any infections,
and this is my tenth week without antibiotics or infection. I think my record
before was three weeks!... When you have bronchiectasis, as long as you can keep
your lungs clear, happy days. That is the most important thing.” [B2]
Some healthy participants (38%) also discussed perceived improvements post-IMT:
“I definitely think my lung capacity is improved . . . I decided to go for a little
run and I was really shocked my breathing had improved . . . I definitely felt the
benefit from it, which was surprising actually. I think it has definitely made a
difference. I know a couple of friends of mine are quite jealous.” [H10]
However, they could not be confident that their perceived improvements were at-
tributable to IMT alone:
“There’s definitely been an improvement in my training over time, but I don’t
know whether that was necessarily because of this device.” [H5]
3.3.4. Future Improvements
Adherence
Despite the positives, participants did voice some areas they would like to improve.
Specifically, some bronchiectasis patients, despite excellent adherence to the training pro-
gramme, thought the training programme was ‘too long’ (30%):
“Tiresome three times a week . . . it was getting to be a bit of a pain after eight
weeks . . . Possibly if it could get condensed to fit into your lifestyle more.” [B4]
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Which was also voiced by the healthy participants and would have potentially helped
with adherence in this cohort (75%):
“If you could condense it into a shorter training period, that would definitely
help in making me complete more sessions.” [H5]
Extrinsic Feedback
Participants, irrespective of health status, suggested more extrinsic feedback to help
with motivation, while also providing rewards:
“I would have liked something like a smiley face or a ‘hip hip hooray! You’ve
done it, well done’!” [B1]
“I think from a sort of motivation point of view, it may sound silly, but just to
have a ‘well done, that was better than last time, you’ve improved this much,’
‘you’re nearly there, keep on going,’ and ‘you’re doing better than you have
previously done.’ So, that would help motivate you.” [H6]
Despite participants exhibiting goal setting, they would also like the app to provide
tangible goals that they have to reach:
“If it set you targets to achieve within a certain period. That would make it far
more worthwhile.” [B4]
“You could have a set target from the data . . . you know ‘can I get closer to the
target’? Without targets, it was difficult to know what you could improve on or
whether you were improving.” [H9]
4. Discussion
This study revealed that an eight-week, home-based IMT programme elicited signifi-
cant and clinically meaningful increases in inspiratory muscle strength and endurance in
both bronchiectasis and healthy participants, with healthy participants also significantly
enhancing expiratory flow and exercise capacity. Whilst no additional adaptations were
shown at 16 weeks, IMT once per week was sufficient to maintain those benefits already
elicited. These physiological benefits were enabled by a high adherence to the IMT pro-
tocol, with participants reporting that IMT was enjoyable and that they perceived health
and well-being benefits. This therefore suggests that IMT may represent an effective and
palatable alternative to traditional pulmonary rehabilitation programmes in those with
bronchiectasis.
As bronchiectasis is associated with respiratory muscle weakness [5–7], the clinically
meaningful improvement in MIP observed after eight weeks of IMT in the current study is
of clinical importance. A recent systematic review and meta-analysis concluded that RMT
may improve the strength of the respiratory muscles [16], specifically low-intensity IMT
(30% MIP) improved MIP by 39% [5], while a progressive overload-based IMT programme
(20–70% MIP) elicited improvements of 44% [6]. However, in contrast to the present study,
both Newall (2005) [5] and Ozalp et al. (2019) [6] found significant improvements in MEP
of 44% and 12%, respectively. Indeed, whilst the present study found improvements in
MEP, these were not statistically significant or clinically meaningful. Such discrepancies
may be due to the small sample size in the present study, though it is noteworthy that these
findings are in accord with Harver and colleagues (1989) [36] who found that eight weeks
of high-intensity IMT improved MIP, but not MEP, in individuals with COPD. As such, the
physiological effect of IMT on expiratory muscles remains unclear. It has, however, been
hypothesised that inspiring against a resistance, as is the case in IMT, could increase the
activation of the expiratory muscles by force extension, leading to an increase in MEP [6].
Elsewhere, it has been postulated that increased inspiratory muscle strength results in
better thorax expansion, enabling a greater elastic recoil, that could improve MEP and
PEF [37]. Decreased expiratory muscle strength can have detrimental effects in bronchiec-
tasis patients on their effectiveness of coughing and removal of airway secretions [8,9],
Int. J. Environ. Res. Public Health 2021, 18, 3051 13 of 17
therefore, further research is required to determine the effect, and underlying mechanism,
IMT has on respiratory muscle function.
Lung function parameters were not affected by IMT in the present intervention. This is
in line with previous research that found eight weeks of high-intensity IMT increased MIP
but had no effect on FEV1 or FVC in those with COPD [36], CF [37] or bronchiectasis [7].
Despite there being no significant improvements in respiratory function post-IMT, MIP
values were significantly associated with pulmonary function in those with bronchiectasis.
It could therefore be postulated that those with inspiratory muscle weakness may suffer
from more severe airflow obstruction and greater lung hyperinflation. This is in accord
with previous research that found a positive correlation between MIP and airflow limitation
in a COPD population [38,39].
Both SMIP and inspiratory duration are emerging as key clinical markers across
several populations [19,40], with suggestions that they are both superior markers of inspi-
ratory performance than MIP [41]. In combination, they provide a more comprehensive
assessment of identifiable characteristics of respiratory muscle weakness or fatiguabil-
ity [40], while potentially providing greater ability to identify outcomes associated with
mortality risk in individuals with COPD [41,42]. The significant improvements in SMIP
and inspiratory duration exhibited post-IMT in the present study are therefore of particular
interest. In COPD, greater SMIP is independently related to reduced airflow limitation, less
dyspnoea and increased six-minute walk test (6MWT) distance [42]. Like SMIP, increased
inspiratory duration is reported to be associated with an increase in distance walked in
6MWT [42]. Therefore, the current improvements could be postulated to translate to
meaningful enhancements in functional exercise capacity.
Exercise intolerance is often reported in those with bronchiectasis, the basis for which
is likely to be multifaceted and includes decreased ventilatory efficiency, altered respiratory
mechanics, insufficient gas exchange, expiratory flow limitation and increased dynamic
hyperinflation [2,4]. Earlier studies have reported significant improvements in intermittent
shuttle walk test distance in people with bronchiectasis [5,6]. However, congruent to earlier
studies [7], IMT was not associated with any change in VO2max in those with bronchiectasis
in the current study, despite participants reporting perceived improvement in their physical
ability to undertake activities of daily living. These apparent discrepancies in the effect
of IMT on exercise capacity are perhaps more likely to be attributable to the measure of
exercise capacity utilised within the studies. Specifically, the current cardiopulmonary
exercise testing (CPET)-derived values provide an accurate measure of maximal exercise
capacity, the clinical significance of which is increasingly evident with regards to predicting
prognosis in numerous clinical conditions [43]. However, the applicability of this measure
to functional capacity and daily activities has been questioned [44], with suggestions that
measures such as the 6MWT distance may be more applicable to bronchiectasis due to
its relatedness to everyday activity [45]. The discrepancies in the effect of VO2max are
contradictory to what might be expected, given the well-established relationship between
baseline fitness and the magnitude of change elicited by traditional exercise interven-
tions [46]. Therefore, it could be speculated that those with bronchiectasis could have
different sites or mechanisms of exercise intolerance, that are perhaps less effected by IMT
or require a greater dose, be that in terms of intensity, frequency, or duration, for beneficial
changes to be manifested. Therefore, future IMT studies should consider incorporating
measures of functional capacity and assessing the effect of IMT on the underlying causes
of functional capacity limitations.
Although the value of patient involvement in clinical research is well established [47],
few studies have specifically explored the opinions, experiences and/or needs of those
with bronchiectasis [48]. Moreover, whilst Hoffman et al. (2018) [10] found that individuals
with chronic lung disease perceived IMT to be of benefit and to increase their confidence in
their disease management, our understanding of patients’ motivations to complete IMT
is limited. More specifically, no research has previously applied or examined motivation
theories within this population. Importantly, IMT elicited high levels of intrinsic moti-
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vation in the bronchiectasis participants in this study, who endorsed and valued their
involvement in the intervention, reporting satisfaction, interest and engagement. A critical
motivating factor for participants desire to train was the live biofeedback, allowing the
adoption of mastery orientated goals, which have been shown to be positively associated
with effort in physical activity and exercise interventions [49]. Furthermore, high levels of
motivation were reflected in the increased levels of autonomy and perceived competence
and low levels of amotivation and controlled regulation in bronchiectasis compared to
healthy participants. High levels of autonomy have been associated with positive health,
behavioural and psychological outcomes, such as adherence to treatment regimens [50].
Contrastingly, controlled forms of amotivation, as reported in the healthy group, have
been linked to poorer adherence [51]. The differences in motivation between groups could
explain the better adherence noted in bronchiectasis participants. Indeed, enjoyment, en-
hanced autonomy and competency are important factors for long-term adherence in clinical
populations [52,53]. Such high adherence to the IMT protocol in those with bronchiectasis is
discordant to research utilising other treatment regimes in this population [54]. Adherence
to such treatment programmes has also been associated with pulmonary exacerbations [54],
reinforcing the potential utility of IMT as a viable rehabilitation strategy for those with
bronchiectasis.
Previous research found that patients with bronchiectasis experience feelings of anx-
iety and fear of exacerbation [55]. Indeed, the main motivations for being physically
active and to undertake IMT in our cohort were centred around the management of their
bronchiectasis and their desire to improve their health. Patients reported perceived im-
provements in their physical ability, a better ability to expectorate sputum in comparison
to using traditional methods, such as the Acapella® (Smiths Medical, Wampsville, NY,
USA), and a reduction in exacerbations during the intervention, which they attributed
solely to IMT. Of importance, impaired clearance of sputum results in a vicious cycle of
colonisation and infection of the bronchi with pathogenic organisms, dilation of bronchi,
pulmonary exacerbations and further production of sputum [56] and therefore the ability
to remove sputum is a key finding. Indeed, this is congruent with previous research which
found that training protocols incorporating ≥80% MIP are better at enhancing mucus
transport, due to higher flow rate as a result of the higher pressure elicited [57]. Conversely,
previous research found that sputum clearance only increased with the Acapella®, which
was preferred by patients compared to threshold IMT [57]. However, it is pertinent to
note that sputum clearance was self-reported in the present study, which is subject to bias.
Future IMT research should therefore utilise sputum volume measurements.
Reductions in reported exacerbations as a result of the IMT intervention is also an im-
portant finding. Indeed, the economic burden of exacerbation in those with bronchiectasis
resulting in hospitalisations is significant [58]. Unsurprisingly, the convenience of being
able to train at home was highlighted as a key enabler, particularly in a population with
increasing treatment burdens [59]. Therefore, the cost-effective, home-based nature of IMT
could be advantageous in those with bronchiectasis.
Despite numerous strengths, this study is not without its limitations. The lack of age-
and sex-matched controls could explain the discrepancies in exercise capacity and, more
specifically, the lack of perceived physical improvement in the healthy cohort. Indeed,
the significantly younger healthy population mean such results should be interpreted
with caution. Despite the recruitment of age- and sex-matched controls, the onset of
COVID-19 precluded the completion of post-intervention testing. It should also be noted
that an a-priori power calculation suggested that a sample size of 13 participants per
experimental group was required. Further, the implementation of an IMT protocol is likely
to be associated with a learning effect. However, the magnitude of change observed in
the current study exceeds those anticipated, suggesting changes are unlikely to be solely
attributable to learning effects. Finally, the relatively small sample size limits statistical
power and interpretation of the data. However, the application of MCIDs enables studies
Int. J. Environ. Res. Public Health 2021, 18, 3051 15 of 17
to be adequately powered with fewer participants [60,61] and has been highlighted as more
important for future treatment decisions [62].
5. Conclusions
In conclusion, an eight-week IMT programme significantly increased inspiratory
strength, respiratory endurance, perceived competence and autonomy in those with
bronchiectasis. Furthermore, bronchiectasis patients perceived an improvement in their
physical ability and had high levels of intrinsic and extrinsic motivation to complete IMT.
IMT, therefore, appears to be an effective and palatable tool to enhance physiological and
psychological health in those with bronchiectasis.
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